Keros Therapeutics, Inc. Stock Price, News & Analysis

Keros Therapeutics (NASDAQ: KROS) has concluded its strategic alternatives review and announced plans to return $375 million in excess capital to stockholders. The company's Board of Directors unanimously approved this decision while maintaining focus on developing KER-065, their lead product candidate for neuromuscular diseases, particularly Duchenne muscular dystrophy. The strategic review process, led by the Board with assistance from outside advisors, evaluated various options including company sale, business combinations, pipeline investment, and capital return. The specific terms and structure of the capital return will be announced at a later date. Lead Independent Director Jean-Jacques Bienaimé emphasized that this decision reflects careful consideration of capital requirements, stockholder feedback, and confidence in Keros's potential to deliver meaningful therapeutic benefits to patients.

Keros Therapeutics (NASDAQ: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, announced that CEO Jasbir S. Seehra will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for June 9, 2025, at 9:20 a.m. Eastern time. The event will be accessible via live audio webcast, with a replay available on the company's investor relations website for 90 days after the event.

Keros Therapeutics (NASDAQ: KROS) announced the discontinuation of its cibotercept (KER-012) development program for PAH following safety concerns in the Phase 2 TROPOS trial. The trial was halted after observing pericardial effusions at multiple dose levels. In response, the company announced a corporate restructuring that includes a 45% workforce reduction, leaving 85 full-time employees, expected to result in $17 million in annual cost savings. The Strategic Committee of the Board continues to evaluate strategic alternatives, including potential sale of the company, pipeline investment, or return of capital to stockholders. An update on this strategic review is expected by June 9, 2025.

ISS, a leading proxy advisory firm, has recommended that Keros Therapeutics (KROS) stockholders withhold votes from directors Dr. Mary Ann Gray and Dr. Alpna Seth at the upcoming June 4, 2025 Annual Meeting. ADAR1 Capital Management, Keros's largest stockholder with a 13.3% stake, supports this recommendation, citing concerns about corporate governance. The company plans to disclose its strategic review results five days after the Annual Meeting, a timing that ADAR1 criticizes. Dr. Daniel Schneeberger, ADAR1's Managing Partner, argues that Keros's cash balance is excessive compared to its clinical opportunities and calls for a significant return of capital to shareholders.

Keros Therapeutics (NASDAQ: KROS) urges stockholders to vote "FOR" three director nominees at its upcoming Annual Meeting on June 4, 2025. The company is conducting a strategic review process, with an update expected by June 9, 2025, to evaluate options including potential sale, business combinations, pipeline investment, and/or capital return. Keros highlights its pipeline progress, including: KER-065 for Duchenne muscular dystrophy, advancing to Phase 2 in Q1 2026; elritercept (KER-050) licensed to Takeda in a deal worth up to $1.3B ($200M upfront + $1.1B in milestones); and cibotercept (KER-012) for PAH, with topline Phase 2 data expected in Q2 2025. The company faces opposition from ADAR1 Capital Management, which is pushing for immediate liquidation. The board emphasizes its independence (8 of 9 directors) and expertise in biotech/pharma sectors.

ADAR1 Capital Management, the largest shareholder of Keros Therapeutics (NASDAQ: KROS) with a 13.3% stake, has released an investor presentation detailing its reasons for opposing the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the company's Board of Directors. The decision will be voted on at Keros' Annual Meeting of Stockholders scheduled for June 4, 2025.

Keros Therapeutics (NASDAQ: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in the Bank of America 2025 Global Healthcare Conference. The company's CEO, Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on May 13, 2025, at 8:00 p.m. Eastern time. The presentation will be accessible via live webcast, with a replay available on the company's investor relations website for 90 days after the event.

Keros Therapeutics (NASDAQ: KROS) has responded to ADAR1 Capital Management's recent communications regarding the upcoming 2025 Annual Meeting. The company's Board announced it is conducting a strategic review process through an independent committee to evaluate options including a potential sale, continued pipeline investment, or return of capital to shareholders. The review follows a significant $200 million upfront payment from a licensing deal with Takeda, which could yield up to $1.1 billion in additional milestones plus royalties.

ADAR1 has opposed the re-election of two independent directors unless their CIO is added to the Board, pushing for immediate capital return to shareholders. Keros's Board, comprising nine directors (eight independent), recommends shareholders vote "FOR" its three director nominees at the June 4, 2025 Annual Meeting. The company highlights its strong cash position, funding operations into 2029.

ADAR1 Capital Management, Keros Therapeutics' (NASDAQ: KROS) largest stockholder with a 13.3% stake, has released an open letter expressing concerns about the company's performance and direction. The activist investor announced plans to withhold votes for directors Dr. Mary Ann Gray and Dr. Alpna Seth at the June 4, 2025 stockholder meeting.

ADAR1 criticizes Keros for concerning clinical results in two drug candidates (KER-012 and KER-065) and calls for major restructuring, including a 70% headcount reduction and return of excess capital to shareholders. The company holds over $720 million in cash as of March 31, 2025. ADAR1 believes their proposed changes could deliver $24-35 per share in value, focusing on KER-050's partnership with Takeda, which they estimate could achieve $2 billion in peak sales.